HLLY heads into its Q1 2026 print with the stock already under real pressure, raising the stakes for what management says about the back half.
The stock fell 13% on May 6 alone, closing at $2.87 — down 10% on the week and 7% over the past month. Despite that sell-off, options positioning has actually grown more bullish, not less. The put/call ratio has dropped to 0.77, well below its 20-day average of 1.10. Earlier in the year, the PCR was running above 1.80 through March and into mid-April — a defensive posture that has since unwound sharply. Options traders are now carrying more calls than has been typical in recent months, a notable divergence from the price action.
Short interest does not amplify the bearish case. At 1.5% of the free float, shorts have barely moved — up just 1% on the week, and the borrow market is exceptionally loose. Availability runs at 4,589% of short interest, meaning shares to borrow are plentiful at essentially no cost (0.47% annually). The ORTEX short score of 31.8 sits in the lower half of the universe. None of the pressure showing up in the price is coming from short sellers piling in.
The analyst debate revolves around timing. Bulls point to a brand portfolio with genuine competitive depth in the performance aftermarket, and argue that tariff headwinds are manageable through pricing and sourcing adjustments. The mean analyst price target of $5.00 implies 74% upside from current levels — though Canaccord Genuity's February target raise to $8.00 looks increasingly optimistic given the stock now trades at $2.87. The bear case is really a timing question: Holley guided for back-half weighted 2026 growth, citing weak early-year weather and new product launches still ramping. Q1 is therefore unlikely to be the company's strongest quarter by design. The EV/EBITDA multiple at 6.7x and an earnings yield of 11% suggest the stock is cheap on trailing numbers — but cheap has not been a sufficient catalyst.
Insider activity has tilted negative. The CFO and an executive vice president both sold shares in March at prices between $2.72 and $3.46 — above current levels. The CEO sold in December at $4.24. Meanwhile, BlackRock and Vanguard both added materially in Q1, with BlackRock increasing its position by over 1.1 million shares.
Thursday's print will test whether Q1 revenues and margins were damaged enough by early-year softness to push back the recovery timeline — and whether management's back-half conviction is strong enough to hold the stock anywhere near current analyst targets.
See the live data behind this article on ORTEX.
Open HLLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
